SeaStar Medical (ICU)
Builds extracorporeal immunomodulation cartridges for acute kidney injury care.
Something off on this page? Send us feedback.
Sells a pediatric extracorporeal immunomodulation cartridge to US hospitals for a narrowly labeled sepsis-related acute kidney injury use. Revenue comes from direct product sales, while the broader adult SCD platform remains tied to pivotal clinical data, FDA review, and the CRRT treatment workflow.
Develops extracorporeal immunomodulation therapies around its Selective Cytopheretic Device, which binds, calms, and releases highly activated neutrophils and monocytes within a renal-replacement-therapy circuit. Its commercial product, pediatric QUELIMMUNE, is a single-use cartridge/tubing therapy for a narrow FDA-approved group of critically ill patients with sepsis-related acute kidney injury who require renal replacement therapy.
Sells QUELIMMUNE directly to US hospitals and executes post-approval evidence collection through the SAVE registry. The adult SCD remains in a pivotal trial alongside CRRT, so its commercial entry depends on clinical results and regulatory approval. All sales are US-only, while cartridge supply, CRRT pumps, regional citrate anticoagulation, calcium-replacement solutions, hospital workflows, coverage, and reimbursement shape use of the platform.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.0M · Total debt $0 · Total assets $8.6M · Shareholders' equity $4.3M
- Revenue
- $615.0K
- Operating income
- −$3.8M
- Net income
- −$3.7M
No dividends on record.
| Institutions | 3.60% | 158.6K shares | |
|---|---|---|---|
| 19 holders · as of Jun 30, 2026 | |||
| Insiders | 13.16% | 579.9K shares | |
| 9 holders · as of Aug 19, 2026 | |||
| Other | 83.24% | 3.67M shares | |
| remainder | |||
4.41M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (4.41M in the company's Sep 23, 2026 report, 2.84M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mitchell P. KopinInsider | 10.06% | 443,253 | filed May 13, 2026 |
Opportunity Master Fund, SPC – Segregated Master Portfolio BInstitution | 6.32% | 278,436 | filed May 11, 2026 |
Eric SchlorffInsiderofficer: Chief Executive Officer | 1.14% | 50,140 | filed Jul 2, 2026 |
Geode Capital Management, LLCInstitution | 1.13% | 49,593 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.75% | 33,091 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Michael Messinger | officer: Chief Financial Officer | +750 | $3.27 |
| Dec 19, 2025 | Jennifer A. Baird | director | +4,200 | $0.2351 |
| Dec 9, 2025 | Michael Messinger | officer: Chief Financial Officer | +14,500 | $0.3516 |
- CytoSorbents
Rival blood-purification cartridges for cytokine-driven critical care.
- Fresenius Medical Care (ADR)
CRRT infrastructure alternative in adult AKI critical care.
- Nuwellis
Pediatric critical-care fluid removal overlaps hospital buying.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SeaStar Medical | $3.52 | −0.42% | $10.0M | — | — | 5.8 | +82.0% |
| CytoSorbents | $5.12 | −3.76% | $16.7M | — | — | 0.4 | +0.2% |
| Fresenius Medical Care (ADR) | $22.43 | −0.33% | $12.09B | 11.8 | 8.7 | 0.5 | −0.7% |
| Nuwellis | $0.8367 | +1.26% | $76.2K | — | — | 0.0 | +14.1% |
| Median | 11.8 | 8.7 | 0.4 | +0.2% |